Careview Communications (OTCMKTS:CRVW) and Bullfrog AI (NASDAQ:BFRG) Head-To-Head Analysis

Careview Communications (OTCMKTS:CRVW) and Bullfrog AI (NASDAQ:BFRG) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings.

Earnings & Valuation

This table compares Careview Communications and Bullfrog AI”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Careview Communications	$8.25 million	N/A	-$4.70 million	N/A	N/A
Bullfrog AI	$60,000.00	167.38	-$6.99 million	($0.69)	-1.28

Careview Communications has higher revenue and earnings than Bullfrog AI.

Profitability

This table compares Careview Communications and Bullfrog AI’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Careview Communications	-39.94%	N/A	-78.17%
Bullfrog AI	N/A	-218.25%	-177.11%

Volatility and Risk

Careview Communications has a beta of -0.58, indicating that its share price is 158% less volatile than the S&P 500. Comparatively, Bullfrog AI has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Careview Communications and Bullfrog AI, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Careview Communications	0	0	0	0	0.00
Bullfrog AI	1	0	0	0	1.00

Insider & Institutional Ownership

1.0% of Bullfrog AI shares are held by institutional investors. 63.9% of Careview Communications shares are held by insiders. Comparatively, 25.2% of Bullfrog AI shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Careview Communications beats Bullfrog AI on 5 of the 9 factors compared between the two stocks.

About Careview Communications

CareView Communications, Inc. provides video monitoring solutions in the United States. Its products include CareView Patient Safety System, a video monitoring tool to improve the practice of nursing, create a better work environment, and make the patient's hospital stay more satisfying, which is used in hospitals, nursing homes, adult living centers, and outpatient care facilities; and CareView Connect, which provides resident monitoring products and services for the long- term care industry; an array of wearable and stationary buttons that allow a resident to summon help either for an emergency or assistance; a mobile app capable of delivering an alert to the caregiver and allows them document information around that alert; and alert management and monitoring system that provides a suite of hardware and software to facilitate a data-driven solution for alert management and monitoring. The company also offers Caregiver Platform that offers caregiver connect mobile application to provide a convenient and intuitive interface to capture critical workflows, such as acknowledging and documenting alert presses by the resident. In addition, it provides SitterView and TeleMedView that allows hospital staff to use CareView's video cameras to observe and communicate with patients remotely. CareView Communications, Inc. is based in Lewisville, Texas.

About Bullfrog AI

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.